Christopher L. Sorge

623 total citations
8 papers, 418 citations indexed

About

Christopher L. Sorge is a scholar working on Oncology, Epidemiology and Pharmacology. According to data from OpenAlex, Christopher L. Sorge has authored 8 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 3 papers in Epidemiology and 3 papers in Pharmacology. Recurrent topics in Christopher L. Sorge's work include Drug-Induced Hepatotoxicity and Protection (3 papers), HIV Research and Treatment (2 papers) and Liver Disease Diagnosis and Treatment (2 papers). Christopher L. Sorge is often cited by papers focused on Drug-Induced Hepatotoxicity and Protection (3 papers), HIV Research and Treatment (2 papers) and Liver Disease Diagnosis and Treatment (2 papers). Christopher L. Sorge collaborates with scholars based in United States and Germany. Christopher L. Sorge's co-authors include George B. Corcoran, Sidhartha D. Ray, Judy L. Raucy, Daniel E. Salazar, Lisa M. Kamendulis, David Parry, Alan P. Venook, Michelle T. Ashworth, Jennifer A. Grabowsky and Gregory M. Springett and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

Christopher L. Sorge

8 papers receiving 406 citations

Peers

Christopher L. Sorge

ONCOL

PHARM

EPIDE

HEPAT

How Sung Lee Singapore

D. Runge Germany

Jean‐Marc Bégué France

T Fox United States

Mariska Geuken Netherlands

Osamu Tagaya Japan

Tamio Fukushima Japan

Mary Petrowski United States

Chad Pope United States

M Agresti Italy

How Sung Lee Singapore

Christopher L. Sorge

189 ×0.9

110 ×0.7

ONCOL

36 ×0.3

PHARM

55 ×0.9

EPIDE

31 ×0.5

HEPAT

Citations per year, relative to Christopher L. Sorge Christopher L. Sorge (= 1×) peers How Sung Lee

Countries citing papers authored by Christopher L. Sorge

Since Specialization

Citations

This map shows the geographic impact of Christopher L. Sorge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher L. Sorge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher L. Sorge more than expected).

Fields of papers citing papers by Christopher L. Sorge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher L. Sorge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher L. Sorge. The network helps show where Christopher L. Sorge may publish in the future.

Co-authorship network of co-authors of Christopher L. Sorge

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher L. Sorge. A scholar is included among the top collaborators of Christopher L. Sorge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher L. Sorge. Christopher L. Sorge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Daud, Adil, Michelle T. Ashworth, Jonathan Strosberg, et al.. (2015). Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 33(9). 1060–1066. 153 indexed citations

Cywin, Charles L., Janice M. Klunder, Eva David, et al.. (1998). Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8. 8-Aryloxymethyl- and 8-Arylthiomethyldipyridodiazepinones. Journal of Medicinal Chemistry. 41(16). 2972–2984. 24 indexed citations

Klunder, Janice M., Charles L. Cywin, Eva David, et al.. (1998). Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes. Journal of Medicinal Chemistry. 41(16). 2960–2971. 27 indexed citations

Salazar, Daniel E., Christopher L. Sorge, Scott W. Jordan, & George B. Corcoran. (1994). Obesity decreases hepatic glutathione concentrations and markedly potentiates allyl alcohol-induced periportal necrosis in the overfed rat.. PubMed. 18(1). 25–33. 16 indexed citations

Ray, Sidhartha D., Christopher L. Sorge, Lisa M. Kamendulis, & George B. Corcoran. (1992). Ca(++)-activated DNA fragmentation and dimethylnitrosamine-induced hepatic necrosis: effects of Ca(++)-endonuclease and poly(ADP-ribose) polymerase inhibitors in mice.. Journal of Pharmacology and Experimental Therapeutics. 263(1). 387–394. 49 indexed citations

Ray, Sidhartha D., et al.. (1991). Extensive Alteration of Genomic DNA and Rise in Nuclear Ca2+ in Vivo Early after Hepatotoxic Acetaminophen Overdose in Mice. Advances in experimental medicine and biology. 283. 699–705. 22 indexed citations

Ray, Sidhartha D., Christopher L. Sorge, Judy L. Raucy, & George B. Corcoran. (1990). Early loss of large genomic DNA in vivo with accumulation of Ca2+ in the nucleus during acetaminophen-induced liver injury. Toxicology and Applied Pharmacology. 106(2). 346–351. 100 indexed citations

Salazar, Daniel E., Christopher L. Sorge, & George B. Corcoran. (1988). Obesity as a risk factor for drug-induced organ injury. VI. Increased hepatic P450 concentration and microsomal ethanol oxidizing activity in the obese overfed rat. Biochemical and Biophysical Research Communications. 157(1). 315–320. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact